TKD-008

TKD-008 is an antimicrobial drug candidate being developed by Therakind in collaboration with the Karolinska Institute, specifically the Iovino Group. The program utilizes Therakind's proprietary DriDose technology, a dry-powder intranasal delivery system designed to optimize the administration of therapeutics. TKD-008 is intended for the treatment of bacterial infections, with a particular focus on pathogens that affect the central nervous system, such as *Streptococcus pneumoniae*. The collaboration leverages the Iovino Group's expertise in bacterial meningitis and blood-brain barrier penetration to develop a nasal-to-brain delivery route that could potentially enhance efficacy and reduce systemic side effects compared to traditional administration methods.